Giorgia Guglielmi
Altered gut bacteria may contribute to fibromyalgia and modifying the gut microbiota could offer a promising approach to reduce symptoms of the condition.
The gut microbiota evolves throughout early life, especially during key transitions phases such as weaning.
A healthy, diverse gut microbiota is important for mounting strong and lasting immune responses to vaccination.
A recent study highlights the potential for dietary interventions in treating C. difficile infection and inflammatory conditions such as inflammatory bowel disease.
Modifying the microbiota could influence multiple sclerosis progression and provide new therapeutic targets.
Gut microbes adapt to exercise demands, favoring energy production over bacterial diversity.
Targeting TudS could be a potential therapeutic approach for treating C. difficile infections.
Each Fusobacterium nucleatum population has unique traits and distribution patterns across body sites and conditions such as colorectal cancer and Crohn’s disease.
Gut microbiota-produced bile acids can be used as therapeutic targets for multiple sclerosis.
Targeting E. lenta or boosting neutrophil function may lead to new treatment strategies for bronchiectasis and related lung diseases.
